Sulfisoxazole Acetyl

CHEMBL1200910 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
309.3 g/mol
LogP
1.3
Phase
4

Sulfisoxazole acetyl is the acetyl ester prodrug of sulfisoxazole used in pediatric oral liquid formulations to mask the bitter taste of sulfisoxazole, providing equivalent systemic antibacterial activity after intestinal hydrolysis to the parent compound. See sulfisoxazole for complete pharmacological details.

Molekularmasse

309,3400 g/mol

LogP

1,30

TPSA

115,00 Ų

Lipinski-Regel der Fünf

Bestanden

Wirkmechanismus

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)N(c1onc(C)c1C)S(=O)(=O)c1ccc(N)cc1

InChI

InChI=1S/C13H15N3O4S/c1-8-9(2)15-20-13(8)16(10(3)17)21(18,19)12-6-4-11(14)5-7-12/h4-7H,14H2,1-3H3

Molecular Formula

C13H15N3O4S

HBD / HBA

1 / 6

Rotierbare Bindungen

3

Schwere Atome

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

Sulfisoxazole acetyl is the acetyl ester prodrug of sulfisoxazole used in pediatric oral liquid formulations to mask the bitter taste of sulfisoxazole, providing equivalent systemic antibacterial activity after intestinal hydrolysis to the parent compound. See sulfisoxazole for complete pharmacological details.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Sulfisoxazole Acetyl is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200910. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6662. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.